07:00 , Sep 5, 2016 |  BioCentury  |  Strategy

Back to School: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
07:00 , Jun 22, 2015 |  BioCentury  |  Strategy

Getting to goal

Bringing in a new CMO with a proven track record in cancer looks like AstraZeneca plc's best shot at recovering from a string of setbacks and hitting the lofty approval and revenue targets it set...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

AZD5363: Phase I data

Data from 36 evaluable patients with HER2-negative metastatic breast cancer in the Phase I portion of the double-blind, placebo-controlled, international Phase I/II BEECH trial showed that the recommended Phase II dose of AZD5363 is twice-daily...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

AstraZeneca, University of Cambridge deal

Under a three-year deal, AstraZeneca, its MedImmune LLC biologics unit and the university partnered to research neurodegenerative diseases. The university will contribute its disease biology expertise, experimental models and tissue samples while the pharma...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

AZD5363: Phase I data

Data from a pair of open-label, dose-escalation, European and Japanese Phase I trials in a total of 92 patients showed that twice-daily oral AZD5363 led to 2 partial responses - 1 ovarian cancer patient and...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Clinical News

AZD5363: Phase I started

AstraZeneca began an open-label, European Phase I trial to evaluate ascending-doses of oral AZD5363 in about 84 patients. AstraZeneca has worldwide rights to the compound from Astex (see BioCentury Aug. 1, 2005). Astex Therapeutics Ltd.,...
07:00 , Apr 18, 2011 |  BioCentury  |  Strategy

Supercharging Astex

SuperGen Inc. and Astex Therapeutics Ltd. are betting that by combining the former's cash with the latter's pipeline and drug discovery platform, they can create a mid-tier cancer company. SuperGen has plenty of cash from Dacogen...